Advanced searches left 3/3

Multiple Myeloma - DOAJ

Summarized by Plex Scholar
Last Updated: 13 May 2022

* If you want to update the article please login/register

Vitamin D as a Potential Player in Immunologic Control over Multiple Myeloma Cells: Implications for Adjuvant Therapies

Multiple myeloma is a plasma cell malignancy with multifactorial etiology. Both in vitro and in vivo, this paper will summarize research published on VD and MM, with a focus on immune system modulation, metabolism of malignant MM cells, synergic activity with anti-MM drugs, and MM-associated peripheral neuropathy.

Source link: https://doi.org/10.3390/nu14091802


The Leading Role of the Immune Microenvironment in Multiple Myeloma: A New Target with a Great Prognostic and Clinical Value

Multiple myeloma is a plasma cell malignancy whose growth thrives in the bone marrow microenvironment. The BMME components' immunoediting may promote MM progression by favoring initial immunotolerance and subsequent tumor cell escape from immune surveillance. Immune effector cells are muzzled and become increasingly anergic in this dynamic process, thus contributing to uncovering drug resistance in unresponsive and relapsed MM patients. New experimental drugs that are currently being tested or already approved may be able to slow down immune clearance and disease progression.

Source link: https://doi.org/10.3390/jcm11092513


The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches

Multiple studies have shown that the immune system can recognize MGUS and MM clonal cells, suggesting that anti-myeloma T cell immunity could be used for therapeutic purposes. In this study, we will explore the potentials of T cell immunotherapy in plasma cell dyscrasias and, in particular, in the disease progression from MGUS to SMM and MM, highlighting the benefits of T cell-based immunotherapeutic approaches in these settings.

Source link: https://doi.org/10.3390/ijms23095242


Blocking the PCNA/NKp44 Checkpoint to Stimulate NK Cell Responses to Multiple Myeloma

The NKp44 receptor interacts with PCNA and can inhibit NK cells' functions. PCNA's expression and function on MM cells was investigated in vitro. First, we demonstrate that PCNA is present on five out of six cell lines' cell membranes, as shown by the novel anti-PCNA mAb developed to detect membrane-associated PCNA. We stained primary bone marrow mononuclear cells from MM patients and found significant staining of membrane-associated PCNA in the fraction of CD38+ CD138 + BM cells that contain the MM cells.

Source link: https://doi.org/10.3390/ijms23094717


Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen

Mesenchymal stem/stromal cells, which make up the bone marrow stroma's primary cellular compartment, are self-renewing and multipotent progenitors. Melflufen is a new anticancer peptide conjugate compound for patients with refractory multiple myeloma. We investigated the cytotoxicity of melflufen, melphalan, and doxorubicin in healthy human bone marrow-derived MSCs, as well as how these drugs influence BMSC proliferation. We established co-cultures of BMSCs with MM. 1S myeloma cells to see if BMSCs improve or decrease the cytotoxicity of melflufen, melphalan, bortezomib, and doxorubicin. We investigated how the drugs affected BMSC differentiation into adipocytes and osteoblasts, as well as the BMSC-supported establishment of vascular networks. Our findings revealed that BMSCs were more sensitive to melflufen than to melphalan. The cytotoxicity of melflufen in myeloma cells was not influenced by BMSC co-culture, as was the case for melphalan, bortezomib, and doxorubicin.

Source link: https://doi.org/10.3390/cells11091574


Improvement in Post-Autologous Stem Cell Transplant Survival of Multiple Myeloma Patients: A Long-Term Institutional Experience

Multiple myeloma accounts for 1. 8% of all new cancer cases in the United States, according to a retrospective survival review of newly diagnosed MM patients receiving ASCT from 1992 to 2016. Patients of the 1001 consecutive NDMM were eligible. Patients aged 65 years and > 65 years old respectively showed dramatic improvements in both PFS and OS. Both standard-risk and high-risk patients were seen with improved PFS and OS. NDMM patients' survival rates have greatly improved largely due to the use of novel drugs and post-ASCT maintenance.

Source link: https://doi.org/10.3390/cancers14092277


Clinical Considerations for Immunoparesis in Multiple Myeloma

Multiple myeloma is a common clonal plasma cell disorder, accounting for 17% of hematologic malignancies. Multiple myeloma patients must be aware of potential complications due to immunoparesis in the diagnosis of multiple myeloma. The elevated risk of infection in multiple myeloma is likely, at least in part, due to immunoglobulin suppression, although not explicitly stated in a large data set. Following myeloablative therapy and autologous HSCT, although not within the diagnostic criteria for multiple myeloma, multiple myeloma's presence and degree of immunoparesis should be examined for prognostication, and immunoglobulin recovery should be monitored following myeloablative therapy and autologous HSCT, several myeloma.

Source link: https://doi.org/10.3390/cancers14092278


RR Myelo POINT: A Retrospective Single-Center Study Assessing the Role of Radiotherapy in the Management of Multiple Myeloma and Possible Interactions with Concurrent Systemic Treatment

Background and purpose: Although chemotherapy, biologic agents, and radiotherapy are all staples of multiple myeloma therapy, the body's therapy of multiple myeloma is limited, the body's randomized systemic treatment and RT research is also skewed, and the optimal RT dose is also unknown. Radiotherapy was successfully administered to 96. 6% of the population, with only hazy doses for 10 > 38 Gy and CST in over 60%; however, biologically based doses of ten > 38 Gy and CST were significantly associated with elevated risks of toxicity in more than half of the accesses; CST and BED 10 had no effect on the toxicity at one and three months, with side effects grade 2 reported only for 4. 6 percent of the accesses. Conclusion: Radiotherapy delivered optimal pain control and fair toxicology, despite BED 10 and CST; however, the radiotherapy protocols with higher BED 10 and CST improved the already excellent radiological disease prevention.

Source link: https://doi.org/10.3390/cancers14092273


Multivariant Transcriptome Analysis Identifies Modules and Hub Genes Associated with Poor Outcomes in Newly Diagnosed Multiple Myeloma Patients

The molecular mechanisms underlying chemoresistance in some newly diagnosed multiple myeloma patients receiving standard therapy are unclear. Identifying clinically relevant gene networks associated with MM death can lead to novel methods, drug targets, and prognostic biomarkers that may help with disease diagnosis. Using two separate sample t -tests, gene expression in patients with poor outcomes was determined differently in patients with poor outcomes. A log-rank Kaplan-Meier and ROC test were used to determine the clinical results of biomarker candidates using overall survival. Within two years, four core modules were highly correlated with MM vital status and differed between the deceased and the living MM patients. G-protein coupled receptor protein, cell-cell adhesion, cell cycle regulation genes, and cell membrane fusion genes were all positively associated with death, according to death.

Source link: https://doi.org/10.3390/cancers14092228


CD229 (Ly9) a Novel Biomarker for B-Cell Malignancies and Multiple Myeloma

The SLAM family of cell-surface molecules, the CD229 homophilic receptor, is predominantly expressed on B and T cells. According to CD229 studies, this receptor acts as a mediator of the proliferation of marginal-zone B cells and other innate-like T and B lymphocytes. Multiple myeloma are among the many studies in this series that used tissue microarrays to determine the expression of CD229 on normal tissues and B-cell malignancies. CD229 was shown to be limited to hematopoietic cells in this case. Moderate CD229 expression was also present in chronic lymphocyte leukemia, follicular, classic mantle-cell, and diffuse large B-cell lymphoma. Given the high success of myeloma cells, we also tested for the presence of soluble CD229 in these patients's serum. Serum samples of soluble CD229 at the time of diagnosis in MM patients could be useful as a prognostic biomarker.

Source link: https://doi.org/10.3390/cancers14092154

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions